Interested in finding out how the late-breaking science presented at SCAI 2024 will impact your practice? Our experts distilled what you need to know:
The CALORI Trial: Cardiac Catheterization With Liberal Oral Intake
A liberal non-fasting strategy before cardiac catheterization significantly improves patient well-being and satisfaction without compromising safety. Few studies have prospectively explored this strategy in such a diverse patient population and with such liberal non-fasting allowances, making this the most comprehensive and generalizable study on this topic to date.
First-in-Human Study With the Novel DurAVR Biomimetic Transcatheter Heart Valve: An Update
The Anteris DurAVR represents new technology in the transcatheter aortic space. The DurAVR valve is on a balloon-expandable platform and utilizes a single leaflet, which is hypothesized to aid in the flow characteristics of the valve. This late-breaking study represents the first-in-human data.
Side branch (SB) occlusion is a risk during unprotected left main (LM) percutaneous coronary intervention (PCI). Understanding the risk factors for SB occlusion can help guide bifurcation stenting strategies and improve outcomes. This late-breaking study examined risk factors for predicting SB occlusion during LM bifurcation PCI.
Peripheral artery disease (PAD) has a widespread impact on the general population, but women are underrepresented in peripheral vascular disease clinical trials. The optimal revascularization strategy for women with femoropopliteal disease remains unknown. This late-breaking study compares endovascular therapy of the EVT with stent implantation versus surgical bypass in patients with symptomatic PAD involving the femoropopliteal segment.
The ENGULF study was a multicenter first-in-human study performed to evaluate the safety and feasibility of using a new dual mechanism moderate bore Hēlo PE (pulmonary embolism) thrombectomy system. How did the device fare?
Radial artery access for Percutaneous Coronary Intervention (PCI) is preferred over femoral artery access according to the 2021 ACC/AHA guidelines in patients with acute coronary syndrome and stable ischemic heart disease (Level of Evidence IA). As the United States has lagged behind many other countries with regard to adopting radial access as first line over the years, this study aimed to evaluate contemporary data on access site selection and associated outcomes.
What's New in Interventional Cardiology
Ground-breaking stories about what's happening in the field.